CN100531769C - 一种治疗痛风的中药组合物及其制备方法 - Google Patents
一种治疗痛风的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN100531769C CN100531769C CNB2006100374984A CN200610037498A CN100531769C CN 100531769 C CN100531769 C CN 100531769C CN B2006100374984 A CNB2006100374984 A CN B2006100374984A CN 200610037498 A CN200610037498 A CN 200610037498A CN 100531769 C CN100531769 C CN 100531769C
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- radix
- gout
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 76
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 201000005569 Gout Diseases 0.000 title claims description 35
- 238000000034 method Methods 0.000 title abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 46
- 239000003826 tablet Substances 0.000 claims abstract description 16
- 239000000341 volatile oil Substances 0.000 claims abstract description 16
- 239000000706 filtrate Substances 0.000 claims abstract description 11
- 239000008187 granular material Substances 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 10
- 239000002775 capsule Substances 0.000 claims abstract description 8
- 239000000284 extract Substances 0.000 claims abstract description 8
- 239000002671 adjuvant Substances 0.000 claims abstract description 6
- 239000000843 powder Substances 0.000 claims abstract description 4
- 238000011282 treatment Methods 0.000 claims description 26
- 229940079593 drug Drugs 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- 238000010992 reflux Methods 0.000 claims description 13
- 238000010438 heat treatment Methods 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 230000002829 reductive effect Effects 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 4
- 229920000858 Cyclodextrin Polymers 0.000 claims description 3
- 239000001116 FEMA 4028 Substances 0.000 claims description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 3
- 229960004853 betadex Drugs 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 abstract description 3
- 238000005303 weighing Methods 0.000 abstract description 2
- 241000132012 Atractylodes Species 0.000 abstract 3
- 240000005428 Pistacia lentiscus Species 0.000 abstract 3
- 240000009022 Smilax rotundifolia Species 0.000 abstract 2
- 235000003205 Smilax rotundifolia Nutrition 0.000 abstract 2
- 235000019441 ethanol Nutrition 0.000 abstract 2
- 239000013521 mastic Substances 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 241000501743 Gentiana macrophylla Species 0.000 abstract 1
- 241000219991 Lythraceae Species 0.000 abstract 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 30
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 24
- 230000000694 effects Effects 0.000 description 24
- 229940116269 uric acid Drugs 0.000 description 24
- 208000002193 Pain Diseases 0.000 description 22
- 230000036407 pain Effects 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 9
- 230000001154 acute effect Effects 0.000 description 9
- 230000008961 swelling Effects 0.000 description 9
- 230000003110 anti-inflammatory effect Effects 0.000 description 8
- 208000004880 Polyuria Diseases 0.000 description 7
- 230000000202 analgesic effect Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 230000035619 diuresis Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 206010018634 Gouty Arthritis Diseases 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 201000001431 Hyperuricemia Diseases 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 4
- 230000036592 analgesia Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 210000001255 hallux Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 238000005096 rolling process Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- RHAXKFFKGZJUOE-UHFFFAOYSA-N 7-acetyl-6-ethyl-3,5,8-trihydroxy-9,10-dioxoanthracene-1,2-dicarboxylic acid Chemical compound O=C1C2=CC(O)=C(C(O)=O)C(C(O)=O)=C2C(=O)C2=C1C(O)=C(CC)C(C(C)=O)=C2O RHAXKFFKGZJUOE-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000013081 microcrystal Substances 0.000 description 3
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical compound [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000003371 toe Anatomy 0.000 description 3
- 235000012431 wafers Nutrition 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 2
- 102100033220 Xanthine oxidase Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 208000026816 acute arthritis Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960001338 colchicine Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 210000005224 forefinger Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000000878 metatarsophalangeal joint Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 210000004935 right thumb Anatomy 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 206010051779 Bone marrow toxicity Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010038419 Renal colic Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046337 Urate nephropathy Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 231100000366 bone marrow toxicity Toxicity 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 239000010382 simiaowan Substances 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960003329 sulfinpyrazone Drugs 0.000 description 1
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100374984A CN100531769C (zh) | 2006-09-05 | 2006-09-05 | 一种治疗痛风的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100374984A CN100531769C (zh) | 2006-09-05 | 2006-09-05 | 一种治疗痛风的中药组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1927330A CN1927330A (zh) | 2007-03-14 |
CN100531769C true CN100531769C (zh) | 2009-08-26 |
Family
ID=37857562
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006100374984A Expired - Fee Related CN100531769C (zh) | 2006-09-05 | 2006-09-05 | 一种治疗痛风的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100531769C (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101590166B (zh) * | 2008-05-27 | 2012-08-08 | 北京因科瑞斯医药科技有限公司 | 一种用于治疗痛风的中药组合物及其制备方法 |
CN101670058B (zh) * | 2009-09-25 | 2011-06-22 | 孙红梅 | 一种治疗痛风的中药组合物 |
CN102949675B (zh) * | 2012-11-21 | 2014-07-30 | 崔海玲 | 一种治疗痛风的中药 |
CN103169900B (zh) * | 2013-04-16 | 2014-11-05 | 董慧芳 | 一种用于治疗痛风的中药制剂 |
CN104887841A (zh) * | 2015-07-03 | 2015-09-09 | 李军 | 治疗痛风的中药制剂 |
CN104887864A (zh) * | 2015-07-03 | 2015-09-09 | 李军 | 一种治疗痛风的制剂及其制备方法 |
CN105106773B (zh) * | 2015-08-14 | 2018-09-21 | 北京中医药大学东方医院 | 一种治疗痛风的中药组合物 |
CN105194460A (zh) * | 2015-10-22 | 2015-12-30 | 刘凯 | 治疗风湿热型痛风发作急性期的中药制剂 |
CN107468955B (zh) * | 2017-09-06 | 2020-07-24 | 大连医科大学 | 治疗痛风性关节炎的中药及制备方法 |
CN110946956A (zh) * | 2019-12-28 | 2020-04-03 | 成都立泰沐成生物科技有限责任公司 | 一种治疗和预防痛风的茶包及其制备方法 |
CN111494508B (zh) * | 2020-03-25 | 2022-03-01 | 广西冠硕科技有限公司 | 一种中药痛风贴的制备方法及其产品 |
-
2006
- 2006-09-05 CN CNB2006100374984A patent/CN100531769C/zh not_active Expired - Fee Related
Non-Patent Citations (2)
Title |
---|
痛风病的中医治疗. 吴茂文.开卷有益.求医问药,第2期. 2003 |
痛风病的中医治疗. 吴茂文.开卷有益.求医问药,第2期. 2003 * |
Also Published As
Publication number | Publication date |
---|---|
CN1927330A (zh) | 2007-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100531769C (zh) | 一种治疗痛风的中药组合物及其制备方法 | |
CN101912593B (zh) | 一种用于治疗痛经的药物及其制备方法 | |
CN103099959B (zh) | 一种治疗溃疡性结肠炎的中药制剂及其制备方法 | |
CN102205107B (zh) | 一种治疗十二指肠溃疡的中药制剂及其制备方法 | |
CN100391521C (zh) | 一种治疗湿热痹的中药及其制备方法 | |
CN101757591B (zh) | 一种治疗慢性结肠炎、直肠炎的中药组合物 | |
CN102813870B (zh) | 一种治疗酒精中毒痛风的中药复方制剂及制备方法与应用 | |
CN104435519B (zh) | 一种治疗原发性痛经的药物组合物 | |
CN103877438B (zh) | 治疗痛风的中药制剂及其生产方法 | |
CN112755140B (zh) | 一种用于治疗痛风性关节炎的药物组合物及其制备方法和用途 | |
CN104815318A (zh) | 一种治疗痛风的中药制剂 | |
CN101745047A (zh) | 一种治疗痛风病的中药组合物及制备方法 | |
CN100546618C (zh) | 一种治疗银屑病的中药制剂 | |
CN104352901A (zh) | 一种治疗痛风的中药 | |
CN100382815C (zh) | 一种治疗风湿痹痛的药物组合物及其制剂 | |
CN101045152A (zh) | 一种治疗慢性盆腔炎伴炎性包块的中药组合物 | |
CN111150799A (zh) | 一种防治高尿酸血症和痛风的组合物及其制备方法和应用 | |
CN106177268B (zh) | 一种治疗阳痿的中药组合物及其制备方法 | |
CN100431578C (zh) | 一种治疗前列腺增生的中药制剂 | |
CN114588241A (zh) | 一种治疗痛风及高血尿酸的中药组合物 | |
CN102552767B (zh) | 治疗肾结石的中药、制备方法及给药方式 | |
CN100333758C (zh) | 一种抗痛风中药的组合物及其制备方法 | |
CN101601840B (zh) | 一种治疗肝豆状核变性的药物 | |
CN104940423A (zh) | 一种治疗痛风的中药制剂 | |
CN103933154A (zh) | 一种治疗痛风病的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU HUAHAI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: GUZHI PHARMACEUTICAL SCIENCE CO., LTD., GUANGZHOU Effective date: 20120619 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 510520 GUANGZHOU, GUANGDONG PROVINCE TO: 510663 GUANGZHOU, GUANGDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120619 Address after: Moon City Road, Guangzhou economic and Technological Development Zone 510663 Guangdong province science and technology innovation base of Guangzhou No. 80 C District sixth floor Patentee after: Guangzhou Huahai Pharmaceutical Co., Ltd. Address before: 510520 Guangdong province Guangzhou Science City Guangzhou lanyue Road No. 80, Guangzhou science and technology innovation base in C District 6 floor Patentee before: Guzhi Medicine Tech Co., Ltd., Guangzhou |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090826 Termination date: 20200905 |
|
CF01 | Termination of patent right due to non-payment of annual fee |